-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Arrow today announced that its RNAi therapy ARO-HSD targeting HSD17B13 has shown certain early effects in a phase I clinical trial involving 5 NASH patients (the rest are healthy volunteers)
Drug source analysis
Drug source analysisWith the success of the mRNA new crown vaccine, RNA drugs have entered the public eye
RNAi is functionally the same as protein degradation technologies such as molecular glue and PROTAC
Of course, RNA also has its own limitations, limited by delivery problems, the current targets are mainly focused on liver targets
Genetic information ranges from DNA to RNA to protein.